Clinical Trial Update: NVG-291 in Spinal Cord Injury Subjects [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial update for NVG-291 in spinal cord injury candidates; the study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Spinal Cord Injury
• Subacute Spinal Cord Injury

Drugs mentioned

• NVG-291

Snippet

Sponsor: NervGen Pharma | Conditions: Spinal Cord Injuries, Chronic Spinal Cord Injury | Phase 1, Phase 2 | Status: RECRUITING